Each week, Charly AI scans over 10,000 data points to uncover the most promising stock opportunities—so you don't have to.
Here are the 10 top BUY picks for the week ending November 16, 2025, ranked from strongest to weakest based on near-term upside potential.
Here’s the #1 stock to watch for the week ending November 16, 2025:
CORMEDIX INC. (CRMD)
- Overall Rating: BUY
- Valuation: UNDERVALUED
- Support Price: $10.75
- Resistance Price: $12.9
CorMedix Inc. has undergone a profound transformation, pivoting from a development-stage company to a profitable commercial entity following its acquisition of Melinta Therapeutics. This strategic move has dramatically diversified its revenue base, which is reflected in an extraordinary 810% year-over-year revenue growth for the third quarter. The company has achieved robust profitability, with a standout operating margin of 49.2% that far exceeds industry peers, signaling highly efficient operations post-acquisition. While certain risks exist, such as a balance sheet now carrying significant intangible assets and a recent build-up in working capital that has temporarily suppressed operating cash flow, these are largely viewed as growing pains associated with integrating a major acquisition. The company's low debt level and strong cash generation provide a solid foundation to manage these integration challenges.
The valuation assessment underscores a significant opportunity, indicating the stock is substantially undervalued with a calculated fair value well above the current trading level. This gap is primarily driven by the market not yet fully pricing in the company's new scale, profitability, and the synergistic benefits from the Melinta portfolio. The strong fundamental outlook is supported by raised management guidance and a pipeline of clinical catalysts, which are expected to sustain momentum. Considering the powerful combination of explosive revenue growth, high profitability, and a compelling valuation gap, the overall assessment for CorMedix stock at this moment is BUY.
Other top picks of the week:
- Charly AI’s analyses and ratings are AI-assisted and for educational purposes only.
- Not investment, legal, or tax advice, and not a solicitation or recommendation to buy, sell, or hold any security.
- Charly AI is not a broker-dealer or registered investment adviser and does not provide personalized advice or act as a fiduciary.
- Information may rely on third-party sources, market data and SEC filings believed reliable, but accuracy and completeness are not guaranteed and content may be incomplete or outdated.
- Past performance is not indicative of future results.
- Investing involves risk, including loss of principal.
- Consider your objectives and consult a qualified advisor before acting.